The weekly litigation news digest is live. Subscribe now

Patent Oppositions in vaccines and immunity drugs industry

Explore the competitive field of vaccines and immunity drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in vaccines and immunity drugs technology and learn how to protect your intellectual property.

Get Patent Opposition Report for vaccines and immunity drugs

Comprehensive Analysis, Strategic Insights & Expert Evaluation – Stay Ahead in Your Patent Challenge.

Download Report

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the vaccines and immunity drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the vaccines and immunity drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Nov 20, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name
Method And Compositions For Cellular ImmunotherapyFRED HUTCHINSON CANCER CENTEROct 8, 2025BOULT WADE TENNANT
Engineered Gamma Delta T-CellsADICET THERAPEUTICSSep 25, 2025STRAWMAN
Combination DrugCHUGAI SEIYAKU KABUSHIKI KAISHASep 24, 2025BOTTI & FERRARI
Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor XCHUGAI SEIYAKU KABUSHIKI KAISHAAug 27, 2025ELKINGTON AND FIFE
Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor XCHUGAI SEIYAKU KABUSHIKI KAISHAAug 26, 2025MAIWALD
A Stable Liquid Formulation Of Fusion Protein With Igg Fc DomainALTEOGENAug 25, 2025DORRIES
Methods Of Using A Bispecific Antibody That Recognizes Coagulation Factor Ix And/Or Activated Coagulation Factor Ix And Coagulation Factor X And/Or Activated Coagulation Factor XCHUGAI SEIYAKU KABUSHIKI KAISHAAug 25, 2025WUESTHOFF & WUESTHOFF
A Stable Liquid Formulation Of Fusion Protein With Igg Fc DomainALTEOGENAug 25, 2025DORRIES
Pre-Filled Syringe And Pre-Filled Syringe Production MethodZEONAug 19, 2025TOPAS ADVANCED POLYMERS
Methods For Improving Safety Of Blood-Brain Barrier TransportF HOFFMANN LA ROCHEJul 30, 2025ZWICKER SCHNAPPAUF & PARTNER

To stay ahead in the competitive vaccines and immunity drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the vaccines and immunity drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Nov 20, 2025
Patent NumberPublication DateTitleApplicantTotal Oppositions
Feb 17, 2021Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of CancerLUDWIG MAXIMILIANS UNIVERSITT MNCHEN10
Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI10
Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB9
May 15, 2019Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHE9
Sep 11, 2019Binding Molecules For Bcma And Cd3AMGEN RESEARCH MUNICH8
Feb 7, 2024Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorSANOFI BIOTECHNOLOGY7
Jan 3, 2024Method For Producing Rna CompositionsCUREVAC7
Aug 21, 2019Binding Molecules For Bcma And Cd3AMGEN RESEARCH MUNICH7
Feb 26, 2020Toxicity Management For Anti-Tumor Activity Of CarsTHE CHILDRENS HOSPITAL OF PHILADELPHIA7
Sep 1, 2021Combination Of A Pd-1 Antagonist And A Vegfr Inhibitor For Treating CancerMERCK SHARP & DOHME7